TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33278125
Drug: New hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: New hydrocortisone formulations and delivery methods
Study: 33278125
Drug: Medications in
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications in combination with hydrocortisone
Study: 33279887
Drug: Panobinostat (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (20 mg oral, weeks 1 and 2), Bortezomib (1.3 mg/m2 subcutaneous, days 1, 4, 8, and 11), Dexamethasone (20 mg oral, day of and the day following bortezomib administration) for 8 cycles (24 weeks)
Study: 33281736
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen (NBO) at 5-8 L/min, 1 hour per session, 3 times daily
Study: 33281950
Drug: Preoperative endocrine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative endocrine therapy (ET) for 3 (±1) weeks
Study: 33282202
Drug: LIQ861 (dry-powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIQ861 (dry-powder inhaled formulation of treprostinil) at doses of 25, 50, 75, 100, 125, and 150 mcg
Study: 33553366
Drug: Neoadjuvant toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant toripalimab plus chemotherapy
Study: 33282726
Drug: Anlotinib treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib treatment
Study: 33283990
Drug: BCH-BB694 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCH-BB694 gene therapy (infusion of autologous CD34+ cells transduced with BCH-BB694 lentiviral vector)
Study: 33284423
Drug: Ixekizumab 80-mg
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80-mg every 2 weeks (Q2W)
Study: 33284423
Drug: Ixekizumab 80-mg
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80-mg every 4 weeks (Q4W)
Study: 33287189
Drug: Pembrolizumab, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, dosage and duration not available
Study: 33287583
Drug: Regional differences
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional differences in treatment approaches
Study: 33287722
Drug: LdT (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LdT (600 mg/day) for 24 weeks, followed by LdT monotherapy until 104 weeks
Study: 33288587
Drug: CCR5 inhibition
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCR5 inhibition treatment
Study: 33288749
Drug: Durvalumab (anti-PD-L1)
Normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in cohort A
Study: 33289590
Drug: Hypomethylating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agent (HMA) guadecitabine
Study: 33289590
Drug: Pre-treatment tumours
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment tumours
Study: 33289660
Drug: Piezocision combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piezocision combined with buccal alveolar bone regeneration using a tunneling approach
Study: 33289920
Drug: Niraparib (NIR)
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib (NIR) at 200 mg every day on D1-7 plus temozolomide (TMZ) at 30 mg/m
Study: 33290245
Drug: Online Psychotherapy
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Psychotherapy Tool (9-week electronically delivered cognitive behavioral therapy program)
Study: 33291741
Drug: Genotyping for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotyping for pharmacokinetic genes (CYP450 and ABC drug transporters)
Study: 33291807
Drug: BoNT-A injections
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT-A injections at baseline and visit 2 (3-6 months later)
Study: 33292050
Drug: Integrated model
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated model (IM) approach to oral health interventions
Study: 33292050
Drug: Daily brushing/flossing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily brushing/flossing
Study: 33292514
Drug: Enhanced recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced recovery program plus goal-directed hemodynamic therapy (ERP + GDHT)
Study: 33292530
Drug: Somatropin (growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin (growth hormone) at a mean dose of 0.03 mg/kg/d (SD, 0.01 mg/kg/d)
Study: 33292530
Drug: Somatropin (growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin (growth hormone)
Study: 33292545
Drug: Preoperative accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative accelerated radiotherapy combined with neoadjuvant and adjuvant chemotherapy (6 cycles of doxorubicin 60 mg/m2)
Study: 33292612
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day for 2 weeks
Study: 33292612
Drug: Atorvastatin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (in vitro on MCF-7 cells)
Study: 33292695
Drug: Panretinal photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panretinal photocoagulation (PRP) treatment
Study: 33292854
Drug: HEAL-ABC intervention
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HEAL-ABC intervention with behaviour change theory and supportive telephone calls every 2 weeks for 3 months, then monthly for 6 months
Study: 33294203
Drug: Ropinirole 0.5
Normalized name: ropinirole 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole 0.5 mg daily and Gabapentin 100 mg daily (combined treatment)
Study: 33294303
Drug: Prostate health
Normalized name: Urinozinc Prostate Health Complex Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate health dietary combination formulation (one daily capsule for 60 days)
Study: 33294812
Drug: MI-Opioid Taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-Opioid Taper
Study: 33294862
Drug: Personalized neoantigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized neoantigen cancer vaccine plus anti-PD-1 therapy
Study: 33295277
Drug: Upper airway
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper airway stimulation (UAS) therapy
Study: 33295823
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow therapy (NHFT) with heated humidified air (flow: 40 L/min with 80% oxygen) during breath-hold (BH) training and treatment.
Study: 33295823
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow therapy (NHFT) during breath-hold (BH) training and treatment.
Study: 33296242
Drug: Melflufen 40
Normalized name: Melflufen
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years)
Study: 33297779
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment tailored to patients' needs based on biomarker identification.
Study: 33298159
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy (NET), up to six sessions with partial telehealth delivery
Study: 33300403
Drug: Hormone-sensitive prostate
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-sensitive prostate cancer (HSPC)
Study: 33300403
Drug: Metastatic hormone-sensitive
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metastatic hormone-sensitive prostate cancer (mHSPC)
Study: 33301227
Drug: Avapritinib 300
Normalized name: avapritinib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib 300 mg once daily
Study: 33301227
Drug: Avapritinib with
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Avapritinib with dose modification
Study: 33301227
Drug: Avapritinib without
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Avapritinib without dose modification
Study: 33301375
Drug: MP0250 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0250 (8 mg/kg, once every 2 weeks)
Study: 33301375
Drug: MP0250 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0250 (12 mg/kg, once every 2 weeks)
Study: 33301375
Drug: MP0250 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0250 (various doses)
Study: 33301630
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (initiated within the first seven days after birth)
Study: 33301630
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early treatment (initiated within the first 72 hours after birth)
Study: 33302031
Drug: Idasanutlin monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin monotherapy
Study: 33302031
Drug: Idasanutlin in
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin in combination with cytarabine
Study: 33302031
Drug: Idasanutlin (MBP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin (MBP formulation)
Study: 33302031
Drug: Idasanutlin (SDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin (SDP formulation)
Study: 33302891
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside >1000 mg
Study: 33302891
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside ≤1000 mg
Study: 33303539
Drug: Sequential follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential follow-up evaluations at 60 and 100 days
Study: 33304267
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive treatment as usual (12 sessions)
Study: 33304282
Drug: Both cannabinoids
Normalized name: Cannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both cannabinoids (800 mg CBD and 20 mg THC)
Study: 33305066
Drug: Laughter prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter prescription (Laughie recording three times daily for 14 days)
Study: 33306187
Drug: Tolvaptan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (mean daily dose 12.7 mg, mean treatment duration 28.0 days)
Study: 33307107
Drug: Tocilizumab (TCZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (TCZ), single-dose intravenous infusion
Study: 33309978
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) alone, doses of 24 to 39.6 Gy
Study: 33310795
Drug: Low first
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low first dose of surfactant
Study: 33310795
Drug: High first
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High first dose of surfactant
Study: 33310883
Drug: Bariatric surgery
Normalized name: Optisource Post Bariatric Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bariatric surgery in patients with GAD antibodies (9 out of 16 patients proceeded with surgery)
Study: 33310883
Drug: Bariatric surgery
Normalized name: Optisource Post Bariatric Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bariatric surgery in patients without GAD antibodies (112 out of 205 patients proceeded with surgery)
Study: 33312759
Drug: CART-133 T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART-133 T cell infusion
Study: 33313307
Drug: Inhaled epithelial
Normalized name: hog epithelia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epithelial sodium channel inhibitor BI 1265162
Study: 33314747
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg plus apatinib combined with liposomal paclitaxel 150 mg/m²
Study: 33314761
Drug: Ertugliflozin co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin co-administered with mefenamic acid (UGT inhibitor)
Study: 33315277
Drug: Everolimus (EVL)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVL) therapy
Study: 33315630
Drug: MAPK pathway
Normalized name: Immunoglobulin g1-lambda, anti-(human tissue factor pathway inhibitor (tfpi, extrinsic pathway inhibitor, epi, lipoprotein-associated coagulation inhibitor, laci))
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAPK pathway inhibitors
Study: 33315720
Drug: Supplemental parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental parenteral nutrition
Study: 33316557
Drug: First-line immunotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line immunotherapy
Study: 33317628
Drug: Home blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home blood pressure (HBP) monitoring (measured twice a day for 7 days at 4, 8, and 12 weeks)
Study: 33317729
Drug: Fampridine treatment
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fampridine treatment (responders)
Study: 33317858
Drug: Tofacitinib (a
Normalized name: tofacitinib (as citrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (a Janus kinase 1/3 inhibitor)
Study: 33318007
Drug: Aztreonam lysine
Normalized name: aztreonam lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam lysine for inhalation solution (AZLI)
Study: 33318012
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (15 to 20 mg/kg/day)
Study: 33318012
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir (40 mg/kg/day)
Study: 33318012
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir (56 mg/kg/day)
Study: 33318012
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (20 to 25 mg/kg/day)
Study: 33319038
Drug: Elbasvir/grazoprevir (EBR/GZR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks
Study: 39140490
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 5-10 mg
Study: 33320245
Drug: Low-dose glucocorticoids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoids (GC), median 1.9 mg/day (IQR 0.6-4.2), mean cumulative prednisone dose 8468 mg, mean duration 44.6 months
Study: 33320245
Drug: Low-dose glucocorticoids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoids (GC), highest cumulative exposure (≥8.4 g)
Study: 33320245
Drug: Low-dose glucocorticoids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoids (GC)
Study: 33320729
Drug: CT ventilation
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT ventilation imaging (CTVI) using the robust Integrated Jacobian Formulation (IJF) method
Study: 33321200
Drug: Open conjunctival
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open conjunctival implantation of the XEN45 Gel Stent
Study: 33321200
Drug: Closed conjunctival
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed conjunctival implantation of the XEN45 Gel Stent
Study: 33322606
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement based on 150 mg of resveratrol
Study: 33323024
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART)
Study: 33323401
Drug: Apatinib 250
Normalized name: lapatinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250 mg orally once daily and camrelizumab 200 mg intravenously every 2 weeks
Study: 33323786
Drug: Injection Pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Pressure (IP) and Minimum Intensity of Stimulation (MIS) during PNB
Study: 33324041
Drug: Budesonide/formoterol (563.3±1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (563.3±1.3 μg/d, n=551)
Study: 33324041
Drug: Fluticasone/salmeterol (1013.8±1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol (1013.8±1.4 μg/d, n=172)
Study: 33324255
Drug: Nabiximols, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols, dosage and duration not specified
Study: 33324899
Drug: Nicotinamide (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (2-4 g/day)
Study: 38068424
Drug: Vojta therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vojta therapy
Study: 33324931
Drug: EVT +
Normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVT + IVT (Endovascular Therapy with Intravenous Thrombolysis)
Study: 39251349
Drug: Niraparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (300 mg once daily in continuous 28-day cycles)
Study: 33327953
Drug: Transfusion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion at a hemoglobin concentration of 8 g/dl (lower-threshold)
Study: 33327953
Drug: Transfusion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion at a hemoglobin concentration of 10 g/dl (higher-threshold)
Study: 33328761
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day of oral ASP0819
Study: 33329075
Drug: Music-listening intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-listening intervention, details on dosage and duration not available
Study: 33329329
Drug: Progressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive treatment for active MRI lesions in MS, specific intervention details not available.
Study: 33330051
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in combination with anthracycline-containing neoadjuvant chemotherapy
Study: 33330076
Drug: Whole-brain irradiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain irradiation therapy (WBRT)
Study: 33330959
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) 2 mg at baseline
Study: 33331996
Drug: ASP3026 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3026 (200 mg)
Study: 33331996
Drug: ASP3026 (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3026 (325 mg)
Study: 33331996
Drug: ASP3026 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3026 (75 mg)
Study: 33331996
Drug: ASP3026 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3026 (125 mg)
Study: 33331996
Drug: ASP3026 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3026 (various doses)
Study: 33332922
Drug: LowTAC/EVR combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: LowTAC/EVR combination
Study: 33332922
Drug: Iscalimab monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscalimab monoclonal antibody
Study: 33332922
Drug: Eculizumab (anti-C5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (anti-C5 monoclonal antibody)
Study: 33334356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preterm birth and LBW
Study: 33334613
Drug: Fendrix® (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendrix® (4 separate 0.5 ml doses administered at 1 month, 2 months, and 6 months)
Study: 33334730
Drug: T cell-based
Normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell-based therapies
Study: 33334808
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity and β-cell function evaluated using HOMA of insulin sensitivity and estimates from oral glucose tolerance tests (Matsuda Index, insulinogenic index, C-peptide index, oral disposition index).
Study: 33335322
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 full-dose booster (SD/SD D56; n=20)
Study: 33335322
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 half-dose booster (SD/LD D56; n=32)
Study: 33335322
Drug: MenACWY comparator
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY comparator vaccine (n=10)
Study: 33336372
Drug: Curative conventional
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curative conventional therapy (radiotherapy)
Study: 33337811
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy in nonelderly patients